


Piretanide

Chemical Properties

CAS No. :	55837-27-9
Formula:	C ₁₇ H ₁₈ N ₂ O ₅ S
Molecular Weight:	362.4
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Piretanide, an orally active loop diuretic, is recognized as a relatively safe and effective pharmacological agent with notable diuretic capacity. Piretanide exhibits potential for research in the treatment of congestive heart failure, with a distinct advantage due to its potassium-sparing properties that may reduce electrolyte imbalance. Piretanide can also be applied within experimental frameworks directed at the study of hypertension, further supporting its utility in cardiovascular research models.
Targets(IC50)	Others,Na-K-Cl cotransporter

Solubility Information

Solubility	DMSO: 200 mg/mL (551.88 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.8 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7594 mL	13.7969 mL	27.5938 mL
5 mM	0.5519 mL	2.7594 mL	5.5188 mL
10 mM	0.2759 mL	1.3797 mL	2.7594 mL
50 mM	0.0552 mL	0.2759 mL	0.5519 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Musini VM, et al. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. *Cochrane Database Syst Rev.* 2015 May 22;(5):CD003825.

Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. *Clin Pharmacokinet.* 1998 Jan;34(1):1-24. Review.

Musini VM, Wright JM, Bassett K, Jauca CD. Blood pressure lowering efficacy of loop diuretics for primary hypertension. *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD003825. doi: 10.1002/14651858.CD003825.pub2.

Review. Update in: *Cochrane Database Syst Rev.* 2012;8:CD003825. PubMed PMID: 19821314.

Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. *Clin Pharmacokinet.* 1998 Jan;34(1):1-24. Review. PubMed PMID: 9474471.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481